KIORA PHARMACEUTICALS

Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.

#SimilarOrganizations #People #Financial #Event #Website #More

KIORA PHARMACEUTICALS

Social Links:

Linkedin

Twitter

Facebook

X

Instagram

Industry:

Biotechnology Medical Pharmaceutical

Founded:

1998-01-01

Address:

Salt Lake City, Utah, United States

Country:

United States

Website Url:

http://www.kiorapharma.com

Total Employee:

11+

Status:

Active

Contact:

7813983811

Email Addresses:

[email protected]

Total Funding:

88.37 M USD

Technology used in webpage:

SPF Mobile Non Scaleable Content Microsoft Exchange Online IPv6 Microsoft Azure DNS Person Schema Google Google Cloud Gravatar Profiles CPanel SSL

Similar Organizations

celator-pharmaceuticals-logo

Celator Pharmaceuticals

Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.

Current Advisors List

not_available_image

Thomas Hancock Board Director @ Kiora Pharmaceuticals
Board_member

mounia-chaoui_image

Mounia Chaoui Board of Directors @ Kiora Pharmaceuticals
Board_member

Current Employees Featured

stephen-from_image

Stephen From
Stephen From President and CEO @ Kiora Pharmaceuticals
President and CEO
2005-01-01

sarah-romano_image

Sarah Romano
Sarah Romano Chief Financial Officer @ Kiora Pharmaceuticals
Chief Financial Officer
2016-01-01

brenda-mann_image

Brenda Mann
Brenda Mann VP, Research & Development @ Kiora Pharmaceuticals
VP, Research & Development
2016-01-01

alain-maiore_image

Alain Maiore
Alain Maiore Director @ Kiora Pharmaceuticals
Director

stephen-from_image

Stephen From
Stephen From Executive Chairman @ Kiora Pharmaceuticals
Executive Chairman
2021-02-01

not_available_image

Morton Goldberg
Morton Goldberg Director @ Kiora Pharmaceuticals
Director

stefan-sperl_image

Stefan Sperl
Stefan Sperl Executive Vice President CMC and Operations @ Kiora Pharmaceuticals
Executive Vice President CMC and Operations
2020-12-01

brian-m-strem_image

Brian M Strem
Brian M Strem President, CEO & Director @ Kiora Pharmaceuticals
President, CEO & Director
2021-07-01

not_available_image

Michael Mullen
Michael Mullen Director @ Kiora Pharmaceuticals
Director

not_available_image

Praveen Tyle
Praveen Tyle Director @ Kiora Pharmaceuticals
Director

Stock Details

Company's stock symbol is NASDAQ:KPRX

Acquisitions List

Date	Company	Article	Price
2016-03-07	Jade Therapeutics	Jade Therapeutics acquired by Kiora Pharmaceuticals	N/A

Investors List

armistice-capital_image

Armistice Capital

Armistice Capital investment in Post-IPO Equity - Kiora Pharmaceuticals

ventech-capital_image

Ventech

Ventech investment in Series D - Kiora Pharmaceuticals

generis-capital-partners_image

Generis Capital Partners

Generis Capital Partners investment in Series D - Kiora Pharmaceuticals

innoven-partenaires_image

Innoven Partners

Innoven Partners investment in Series D - Kiora Pharmaceuticals

medicis-capital_image

Medicis Capital

Medicis Capital investment in Series D - Kiora Pharmaceuticals

natixis-private-equity_image

Natixis Private Equity

Natixis Private Equity investment in Series D - Kiora Pharmaceuticals

innoven-partenaires_image

Innoven Partners

Innoven Partners investment in Series C - Kiora Pharmaceuticals

nexus-medical-partners_image

Nexus Medical Partners

Nexus Medical Partners investment in Series C - Kiora Pharmaceuticals

ventech-capital_image

Ventech

Ventech investment in Series C - Kiora Pharmaceuticals

medicis-capital_image

Medicis Capital

Medicis Capital investment in Series C - Kiora Pharmaceuticals

Key Employee Changes

Date	New article
2021-10-26	EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

Official Site Inspections

http://www.kiorapharma.com Semrush global rank: 1.9 M Semrush visits lastest month: 11.52 K

Host Informations
Whois Informations

Loading ...

More informations about "Kiora Pharmaceuticals" on Search Engine